高敏肌钙蛋白T在慢性心力衰竭中的预后价值:个体患者数据荟萃分析
中位随访2.4年显示,hs-TnT与全因死亡、心血管死亡和心血管住院均独立相关,并显著改善风险预测。
要点
- 在慢性心衰患者中,hs-TnT是全因死亡和心血管死亡的独立预测因子。
- hs-TnT可改善包含性别、年龄、病因、LVEF、eGFR和NT-proBNP的预后模型。
- 18 ng/L切点衍生的预后价值在男女、缺血/非缺血病因及肾功能障碍各亚组中均独立存在。
核心结论
- 在慢性心衰中,高敏肌钙蛋白T是全因死亡、心血管死亡和心血管住院的强独立预测因子,可作为预后分层的额外工具。
研究设计与样本
- 检索Medline、EMBASE、Cochrane Library和Scopus(2017年4月),纳入英文、临床稳定、使用高敏肌钙蛋白检测、有随访且可获得个体患者数据的研究。
- 所有患者均有高敏肌钙蛋白T数据,仅209例同时检测了高敏肌钙蛋白I。
主要发现
- 在包含性别、年龄、缺血与非缺血病因、LVEF、eGFR和NT-proBNP的预后模型基础上,hs-TnT仍独立与全因死亡相关(HR 1.48,95%CI 1.41-1.55,P<0.001)。
- hs-TnT独立与心血管死亡相关(HR 1.40,95%CI 1.33-1.48,P<0.001)。
- hs-TnT独立与心血管住院相关(HR 1.42,95%CI 1.36-1.49,P<0.001),中位随访2.4年。
- hs-TnT加入上述预后模型后显著改善风险预测。
- 曲线下面积衍生的18 ng/L切点在男女、缺血或非缺血病因及肾功能障碍各亚组中对3个终点均具有独立预后价值。
关键数值与推荐
- hs-TnT与全因死亡的独立关联:HR 1.48(95%CI 1.41-1.55),P<0.001。
- hs-TnT与心血管死亡的独立关联:HR 1.40(95%CI 1.33-1.48),P<0.001。
- hs-TnT与心血管住院的独立关联:HR 1.42(95%CI 1.36-1.49),P<0.001。
- AUC衍生的18 ng/L切点对3个终点均具有独立预后价值。
临床怎么用
- 在慢性心衰患者中可检测高敏肌钙蛋白T,将其纳入已建立的风险模型以增强预后分层。
- hs-TnT升高(如>18 ng/L)提示全因死亡、心血管死亡和心血管住院风险增加,可辅助识别高危患者。
- hs-TnT的预后价值在男女、缺血/非缺血病因及肾功能障碍各亚组中均存在,可跨亚组参考。
局限性
- 仅209例患者有高敏肌钙蛋白I数据,无法充分比较hs-TnT与hs-TnI的预后价值。
- 研究纳入条件要求临床稳定且可获得个体患者数据,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most patients with chronic heart failure have detectable troponin concentrations when evaluated by high-sensitivity assays. The prognostic relevance of this finding has not been clearly established so far. We aimed to assess high-sensitivity troponin assay for risk stratification in chronic heart failure through a meta-analysis approach. METHODS: Medline, EMBASE, Cochrane Library, and Scopus were searched in April 2017 by 2 independent authors. The terms were "troponin" AND "heart failure" OR "cardiac failure" OR "cardiac dysfunction" OR "cardiac insufficiency" OR "left ventricular dysfunction." Inclusion criteria were English language, clinical stability, use of a high-sensitivity troponin assay, follow-up studies, and availability of individual patient data after request to authors. Data retrieved from articles and provided by authors were used in agreement with the PRISMA statement. The end points were all-cause death, cardiovascular death, and hospitalization for cardiovascular cause. RESULTS: Ten studies were included, reporting data on 11 cohorts and 9289 patients (age 66±12 years, 77% men, 60% ischemic heart failure, 85% with left ventricular ejection fraction <40%). High-sensitivity troponin T data were available for all patients, whereas only 209 patients also had high-sensitivity troponin I assayed. When added to a prognostic model including established risk markers (sex, age, ischemic versus nonischemic etiology, left ventricular ejection fraction, estimated glomerular filtration rate, and N-terminal fraction of pro-B-type natriuretic peptide), high-sensitivity troponin T remained independently associated with all-cause mortality (hazard ratio, 1.48; 95% confidence interval, 1.41-1.55), cardiovascular mortality (hazard ratio, 1.40; 95% confidence interval, 1.33-1.48), and cardiovascular hospitalization (hazard ratio, 1.42; 95% confidence interval, 1.36-1.49), over a median 2.4-year follow-up (all P<0.001). High-sensitivity troponin T significantly improved risk prediction when added to a prognostic model including the variables above. It also displayed an independent prognostic value for all outcomes in almost all population subgroups. The area under the curve-derived 18 ng/L cutoff yielded independent prognostic value for the 3 end points in both men and women, patients with either ischemic or nonischemic etiology, and across categories of renal dysfunction. CONCLUSIONS: In chronic heart failure, high-sensitivity troponin T is a strong and independent predictor of all-cause and cardiovascular mortality, and of hospitalization for cardiovascular causes, as well. This biomarker then represents an additional tool for prognostic stratification.
引用
- Aimo A, Januzzi JL, Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. 2018. PMID: 29335288. doi:10.1161/CIRCULATIONAHA.117.031560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。